Raoof M, Blakely AM, Melstrom LG, et al. - Data (n = 8,297) from the National Cancer Database (NCDB) for node-positive (N+) and/or margin-positive (R1) pancreatic adenocarcinoma patients diagnosed from 2004 to 2012 who underwent adjuvant chemoradiation (ACR) or adjuvant chemotherapy (AC) was used by the experts in order to examine whether there was evidence of superiority of ACR over AC. Two well-balanced groups of 3,244 patients each were assessed. ACR led to superior OS in comparison with AC alone. Subset analyses exhibited OS advantage of ACR vs AC in N+, R0 patients as well as N+, R1 patients, however, not in node-negative, R1 patients. Hence, addition of radiation to AC was related to a clinically small but significant rise in survival of patients who underwent curative-intent pancreatic resections. This relationship was not evident in patients with microscopically positive margins but node-negative disease.